Business Context and Reporting Period
This Form 8-K Current Report is filed by OncoGenex Pharmaceuticals, Inc. (not Achieve Life Sciences, Inc., as indicated in the metadata) for the reporting period of January 1, 2011. The filing addresses corporate governance changes regarding the appointment and resignation of senior officers and directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Appointment: Michelle Burris was appointed Executive Vice President, Operations, and Chief Financial Officer (CFO), designated as the principal financial officer, effective January 3, 2011.
- Role Clarification: On January 1, 2011, the Board determined that Cameron Lawrence would continue to serve as the principal accounting officer and treasurer. Consequently, the prior designation of Michelle Burris to these specific positions was never given effect.
- Resignation: Michelle Burris resigned from the Board of Directors effective immediately on January 3, 2011.
- Board Composition: The Board fixed its size at six directors following the resignation.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, outlook, management commentary on strategy, specific risks, contingencies, or unusual items. The document is limited to reporting the departure and appointment of officers.
Investor Verification Checklist
- Verify the current status of Michelle Burris's employment with the company following her resignation from the Board.
- Confirm the exact scope of Cameron Lawrence's responsibilities as Principal Accounting Officer and Treasurer.
- Check subsequent filings to confirm the final composition of the six-member Board of Directors.
- Review the company's most recent 10-K or 10-Q for actual financial metrics, as this 8-K contains none.